Illimis Therapeutics

Business Services · South Korea · 11-50 Employees

View Company Info for Free

Overview

Headquarters

18 Heolleung-ro 569-gil, Seoul, 06376, S...

Phone Number

+82 24456877

Revenue

$11.8 Million

Industry

Business Services Research & Development
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1

About Illimis Therapeutics

Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimers. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.Explore more
Illimis Therapeutics's Social MediaPopular SearchesIllimis TherapeuticsIllimis Therapeutics IncSIC Code 87,873NAICS Code 54,541Show more

Illimis Therapeutics Org Chart

PhoneEmail
JB
South Korea flag for contact location.

Chief Operating Officer

PhoneEmail
SJ
South Korea flag for contact location.

Chief Executive Officer, Illimis Therapeutics...

PhoneEmail
SJ
South Korea flag for contact location.

Chief Financial Officer & Chief Operating Off...

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.
YL
South Korea flag for contact location.

Manager

PhoneEmail
SY
South Korea flag for contact location.

Senior Manager

PhoneEmail
JP
South Korea flag for contact location.

Manager(Part Leader)

PhoneEmail
YW
South Korea flag for contact location.

Manager

PhoneEmail
GJ
South Korea flag for contact location.

Group Manager, Research & Development

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is Illimis Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

Illimis Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

Illimis Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Illimis Therapeutics.

Illimis Therapeutics financials insights

Gather financial insights about Illimis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2023

Series A

$15.4M

See All Illimis Therapeutics's Financials Insights

Illimis Therapeutics Tech Stack

A closer look at the technologies used by Illimis Therapeutics

Top Business Services Companies

Frequently Asked Questions Regarding Illimis Therapeutics

What is Illimis Therapeutics's official website?
Illimis Therapeutics's official website is www.illimistx.com
What is Illimis Therapeutics's Revenue?
Illimis Therapeutics's revenue is $11.8 Million
What is Illimis Therapeutics's SIC code?
Illimis Therapeutics's SIC: 87,873
What is Illimis Therapeutics's NAICS code?
Illimis Therapeutics's NAICS: 54,541
How many employees does Illimis Therapeutics have?
Illimis Therapeutics has 11-50 employees
What industry does Illimis Therapeutics belong to?
Illimis Therapeutics is in the industry of: Business Services, Research & Development
What technology does Illimis Therapeutics use?
Some of the popular technologies that Illimis Therapeutics uses are: Cloudflare CDN, Google Tag Manager, jsDelivr, Google Global Site Tag
Who is the CFO of Illimis Therapeutics?
Illimis Therapeutics's CFO is Sang Jeon
How do I contact Illimis Therapeutics?
Illimis Therapeutics contact info: Phone number: +82 24456877 Website: www.illimistx.com
What does Illimis Therapeutics do?

Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimers. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from e... xisting antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.Read More

What are Illimis Therapeutics social media links?
Illimis Therapeutics Linkedin page Illimis Therapeutics Twitter page
Who invested in Illimis Therapeutics?
Illimis Therapeutics has 2 investors including Korea Development Bank and AJU IB INVESTMENT.
Is Illimis Therapeutics a public company?
Illimis Therapeutics is private company therefore does not currently have an official ticker symbol
See more information about Illimis Therapeutics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.